首页> 外文期刊>British journal of ophthalmology >Managing antiplatelet and anticoagulant drugs in patients undergoing elective ophthalmic surgery
【24h】

Managing antiplatelet and anticoagulant drugs in patients undergoing elective ophthalmic surgery

机译:择期眼科手术患者的抗血小板和抗凝药物管理

获取原文
获取原文并翻译 | 示例
       

摘要

The management of antiplatelet and anticoagulant treatment can be challenging for the ophthalmic surgeon with the risk of impaired surgical view or potentially sight-threatening haemorrhage. With the advent of newer medications and the expanding usage of these drugs, there is a need for up-to-date guidance on the subject. This paper describes the current use of modern antiplatelet and anticoagulant drugs in the UK, and reviews the evidence of such treatments in the context of ophthalmic surgery. A multidisciplinary approach has been used to develop a guideline for the management of antiplatelet and anticoagulation treatment in elective ophthalmic surgery. Specifically, guidance is provided on when and how to stop antiplatelet and anticoagulant treatment and, importantly, when to seek specialist medical advice.
机译:对于眼外科医生而言,抗血小板和抗凝治疗的管理可能具有挑战性,存在手术视野受损或潜在视力出血的风险。随着更新的药物的出现和这些药物的广泛使用,需要关于该主题的最新指南。本文介绍了英国目前使用现代抗血小板和抗凝药物的情况,并综述了眼科手术中此类治疗的证据。一种多学科的方法已被用来制定指导眼科手术中抗血小板和抗凝治疗的指南。具体来说,指南提供了有关何时以及如何停止抗血小板和抗凝治疗以及重要的是何时寻求专业医疗意见的指南。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号